SmartCells, Inc. developed SmartInsulin, a once-a-day, self-regulating, injectable formulation for treating diabetes. It is designed to provide several import advantages for diabetics. In 2010, Merck acquired all outstanding stock of SmartCells, Inc. In return, SmartCells shareholders received an upfront cash payment and be eligible to receive clinical development and regulatory milestones for products resulting from the transaction for potential aggregate payments in excess of $500 million. Sales-based payments for products resulting from the transaction will also be payable. In 2010, SmartCells, Inc. was acquired by Merck.
SmartCells, Inc. developed SmartInsulin, a once-a-day, self-regulating, injectable formulation for treating diabetes. It is designed to provide several import advantages for diabetics. In 2010, Merck acquired all outstanding stock of SmartCells, Inc. In return, SmartCells shareholders received an upfront cash payment and be eligible to receive clinical development and regulatory milestones for products resulting from the transaction for potential aggregate payments in excess of $500 million. Sales-based payments for products resulting from the transaction will also be payable. In 2010, SmartCells, Inc. was acquired by Merck.
- Sector
- Life Sciences
- Stage
- Acquired
- Status
- Exit
- Exit Details
- In 2010, Merck acquired all outstanding stock of SmartCells, Inc.